Roland E. Schmieder

TL;DR: The effects of eprosartan on RPF are mediated, at least in part, by an increased bioavailability of nitric oxide in the renal vasculature, which is correlated with the L-NMMA induced decrease in RPF in the combination.

TL;DR: Angiotensin II emerged as a determinant of left ventricular structural adaptation in essential hypertension.

TL;DR: Clinical hesitation in relation to reducing elevated BP to goal levels is putting patients at increased cardiovascular risk and contributing to the substantial health and economic burden associated with uncontrolled BP.

TL;DR: The data suggest that cPP, indicative of the degree of large arterial stiffening, may be helpful to identify responders to RDN.

TL;DR: The ONgoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisARTan 80 mg was not inferior to the angioensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than RAMPril alone, in decreasing morbidity and mortality in patients with cardiovascular disease or high-risk diabetes as discussed by the authors.